ArticleFrontiers in oncology2025
Validation of SRS MapCHECK for CyberKnife patient-specific quality assurance: challenges with small cone sizes.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The CyberKnife system, designed for stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT), considers SRS MapCHECK an effective tool for patient-specific QA (PSQA). This work evaluates the performance of SRS MapCHECK in CyberKnife PSQA, identifies potential sources of inaccuracy in PSQA analysis, and recommends accurate and reliable use of this tool for small fields. Methods: SRS MapCHECK is a promising tool for CyberKnife PSQA due to its compact size and high-resolution 2D detector. It enhances dosimetry accuracy by incorporating correction factors for field size and gantry angle. To validate its effectiveness, PSQAs were performed on CyberKnife plans with various fixed cone sizes for brain SRS cases. Static field dose delivery was tested by rotating robotic arm angles for different fixed cone sizes under various correction settings to assess the impact of these correction factors on dosimetric accuracy. Results: For PSQAs on 12 patient plans, statistically significant negative correlation (spearman correlation Conclusion: This study evaluates the suitability of SRS MapCHECK for PSQA of the CyberKnife system and highlights its limitations. It demonstrates that while SRS MapCHECK is effective for larger fixed cone sizes, it does not ensure dosimetric accuracy for plans involving very small fixed cones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.